Is the GLP-1 Price War Escalating, and What Does it Mean for Eli Lilly

Related Articles

What Does Olumiant's EU Recommendation Mean for Eli Lilly

8 months ago

What's Driving the Bearish Options Activity in Eli Lilly

7 months ago

Has the AI Capex Cold War Escalated, and What Does it Mean for Big Tech

8 months ago

Why Are Institutional Investors Still Bullish on Eli Lilly

7 months ago

Category

You may also like

Stock News•1 months ago

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Eli Lilly's Q2 2026 sales were nearly two-thirds from GLP-1 drugs, as Amylyx and other competitors advance rival GLP-1 candidates, potentially pressuring Lilly's market share.

GLP

Share

Stock News•2 months ago

Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk

Eli Lilly's obesity drug franchise holds a 60–61% US market share, outpacing Novo Nordisk despite pricing pressure. Valuation has compressed to just over 30x forward earnings, reflecting expectations ...

LLY

Share

Stock News•2 months ago

Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity

Eli Lilly's GLP-1 medicines saw lower realized prices but substantially higher sales volume, driven by spotty insurance coverage in the weight-loss market. This pricing dynamic could become a growth o...

GLP

Share